Aurobindo Pharma has announced its consolidated financial results for the quarter ended December 31, 2025, reporting robust revenue growth driven by Europe and antiretroviral (ARV) sales.
Revenue from operations rose 8.4% year-on-year (YoY) to Rs. 8,646 crore, with strong performances in Europe and ARV segments. U.S. formulations revenue grew 2.2% YoY to Rs. 3,739 crore (USD 420 million), while European formulations surged 27.4% YoY to Rs. 2,703 crore (EUR 261 million). Growth Markets revenue remained steady at Rs. 865 crore (USD 97 million), and ARV sales jumped 22.4% YoY to Rs. 376 crore (USD 42 million).
Profitability remained solid, with EBITDA before R&D at Rs. 2,163 crore, representing a 25% margin, and EBITDA before forex and other income at Rs. 1,773 crore, or 20.5% margin. R&D spending, including depreciation, totaled Rs. 409 crore, accounting for 4.7% of revenues.
Net profit for the quarter stood at Rs. 910 crore, including a one-time cost of Rs. 65 crore due to changes in labor code. The company also reported a strong net cash position of USD 251 million after acquiring Khandelwal Laboratories and generated free cash flow of USD 118 million during the quarter. Basic and diluted EPS was Rs. 15.67 per share.
On regulatory progress, Aurobindo received final approval for seven ANDAs from the USFDA, including two previously tentatively approved filings.
Commenting on the performance, K Nithyananda Reddy, Vice-Chairman and Managing Director, said: "Q3 reflected steady execution across Aurobindo’s core businesses, supported by stable demand and the strength of our diversified product portfolio in key markets, including the U.S. and Europe.
"Growth remained measured, with continued focus on operational discipline and a balanced approach to growth and profitability. As we progress our strategic initiatives, we remain cautious yet confident in our ability to support sustainable value creation over the medium term.”
With 91% of revenues from international markets, Aurobindo continues to leverage its diversified portfolio, balancing growth across developed and emerging markets while strengthening its global footprint.
